Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $535.81, for a total transaction of $5,090,195.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $21,707,270.53. The trade was a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

United Therapeutics Stock Down 1.8%

Shares of United Therapeutics stock opened at $522.83 on Friday. The company has a market cap of $22.92 billion, a PE ratio of 18.74, a price-to-earnings-growth ratio of 1.92 and a beta of 0.84. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $549.50. The business has a 50 day moving average price of $495.95 and a 200-day moving average price of $472.65.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue was up 7.4% on a year-over-year basis. During the same period last year, the business earned $6.19 EPS. As a group, research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC grew its position in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the period. Wellington Management Group LLP increased its holdings in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC raised its position in United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after acquiring an additional 295,221 shares during the period. Invesco Ltd. raised its position in United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after acquiring an additional 419,588 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after acquiring an additional 341,383 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. HC Wainwright upped their price objective on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Finally, UBS Group boosted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $549.91.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.